SCHEMBL260363

SCHEMBL260363

OCc1c[nH]cc1CN1CCOCC1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.53
ALOX15 P16050 1/20 0.53
HSD17B10 Q99714 1/20 0.53
ALDH1A1 P00352 4/20 0.45
KDM4E B2RXH2 3/20 0.45
KMT2A Q03164 2/20 0.45
LMNA P02545 1/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
CYP2A13 Q16696 6/20 0.45
MEN1 O00255 1/20 0.44
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
HRH3 Q9Y5N1 2/20 0.42
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14132099 0.79 CYP2A13 (0.57) CYP2C9ALOX15HSD17B10ALDH1A1KDM4E
SCHEMBL2251851 0.76 CYP2A13 (0.64) CYP2C9ALOX15HSD17B10ALDH1A1KDM4E
SCHEMBL28790489 0.75 HTT (0.48) CYP2C9ALOX15HSD17B10ALDH1A1KDM4E
SCHEMBL260803 0.75 CYP2C9 (0.45) CYP2C9ALOX15HSD17B10KDM4EMAPT
SCHEMBL15318201 0.70 CYP2A13 (0.41) CYP2C9ALOX15HSD17B10KDM4EKMT2A
SCHEMBL10005451 0.69 CYP2C9 (1.00) CYP2C9ALOX15HSD17B10ALDH1A1KDM4E
SCHEMBL2025162 0.69 CYP2C9 (0.66) CYP2C9ALOX15HSD17B10ALDH1A1KDM4E
SCHEMBL11202439 0.69 CYP2C9 (0.59) CYP2C9ALOX15HSD17B10ALDH1A1KDM4E
SCHEMBL11193326 0.69 CYP2A13 (0.75) CYP2C9ALOX15HSD17B10ALDH1A1KDM4E
SCHEMBL5753998 0.68 CYP2A13 (0.53) CYP2C9ALOX15HSD17B10ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101987848-B New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing the same SERVIER LAB 2014-06-18 CN disclosed
US-20130331380-A1 DIHYDROINDOLONE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2013-12-12 US disclosed
US-8541412-B2 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2013-09-24 US disclosed
EP-2281822-B1 New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them SERVIER LAB (FR) 2013-01-16 EP disclosed
US-8133889-B2 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2012-03-13 US disclosed
US-20120046287-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2012-02-23 US disclosed
CN-101987848-A New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them SERVIER LAB 2011-03-23 CN disclosed
US-20110034460-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2011-02-10 US disclosed
EP-2281822-A1 New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2011-02-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130331380-A1 DIHYDROINDOLONE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM CYP11B1, SDHA, CYP11B2 CYP2C9 203/4885ALOX15 1221/4885HSD17B10 385/4885
US-20120046287-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them CYP11B1, SDHA, CYP11B2 CYP2C9 203/4885ALOX15 1221/4885HSD17B10 385/4885
US-20110034460-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them CYP11B1, SDHA, CYP11B2 CYP2C9 203/4885ALOX15 1221/4885HSD17B10 385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.